Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 29, 2022 4:31pm
115 Views
Post# 34556757

RE:RE:RE:RE:RE:RE:RE:RE:RE:More on Reverse Splits

RE:RE:RE:RE:RE:RE:RE:RE:RE:More on Reverse SplitsThe fact is that Levesque not so far ago was very affirmative about Thera going alone in a large phase III trial in NASH. Reality catched up to him and he had to start this partner search in order to gradually take his words back, and now it's no longer a phase III but they will ask FDA for a phase IIb/III. That's backpedaling on a big scale for such a small company. 

So it's false to say they did not try to set a positive narrative about their projects to attract attention and interest. The problem is that it failed, as far as we know, nobody was willing to partner with them on acceptable terms. So maybe Levesque learned his lesson out of that, and for oncology he will wait for results before talking too much. Anyway, it is hard to make promises in oncology at this time, they are 6 months late on their initial timeline for phase Ia results. Talk less, deliver more.


SPCEO1 wrote: I am confident realize that equity investing is all about hopes for an as yet undefined future. You often sound more like a bond investor who is solely focused on getting his next coupon paid and therefore often does not look very far at all into the future and is typcially more consumed witht he recent past. So, there is a narrative TH and every other company creates about their future and I think you would agree that TH comes up a little short on creating that narrative. Indeed, you are proof of that yourself as you are consumed with the narrative that this is a failed company given its near 30 year record of futility. TH needs to convince you there is more to look forward to and they would be foolish not to try harder to do that using everything at their disposal to try to nudge you away from that backwards looking narrative. They might not succeed in your case but they should be trying. We are not asking them to be Elon Musk, of course, but we are also not real interested in them being Mortimer Snerd either. 

jfm1330 wrote: I am sure they do other things. I am sure they have talks with potential partners, financial firms, investors, potential investors, cancer experts, and so on. That being said, at this point they don't have much to discuss. They can only discuss hypothetical scenarios since they cannot disclose what they have right now in phase Ia. I think preliminary contacts have been made with all the relevant people, but they will be able to get real only with real reasults. I always come back to this basic point, a good seller is someone with something good to sell. Now they don't have that, or if they have it, they cannot talk about it. I am sure they have a plan in place to be very active if they have something meaningful in their hand, or something that would lead them to think they are on the right path to get that in phase Ib.


SPCEO1 wrote: jfm - When you do something at work, do you just focus on the main goal or do you also try to optimize the situation by getting other aspects of the work sorted out to obtain the best possible overall result. Of course, the main issue is the cancer phase 1a results right now, and there would be no point in doing a reverse split if they are not good, but if they are, there are any number of other things TH can do to make the overall result even better. I know you are smart enough to want to see those things done too. Yes, let's get the primary result we are looking for but let's also optimize the situation to achieve the reatest benefit.

jfm1330 wrote: You have the right to think wathever you want of me. I don't care. That does not change the reality. This company is old and only game changing results will change how it is perceived. If they have something meaningful in cancer the news will go around easily. They need to come out of the phase Ia with results hinting highly at a proof of concept, and then confirm that in phase Ib.


PWIB123 wrote: I'm sorry jfm1330, but you sound like a severely novice investor.  SPC01 is not wrong about how he views the investment world and the need for THTX leadership to engage capital markets, institutional investors, and retail investors in different ways.  He's not wrong about reverse splits either.  One of my other investments did a reverse split two years ago.  It was a brutal period for them in spite of posting incredible results that no one was investing into, but after the reverse split and consistent communication, the stock has gone from $3/share to $30/share.  It's this simple.  If the results are stunning and literally no one is aware or able to buy, it literally will not matter.  THTX needs us investors to be able to capitalize on the results.  There is an art to this science.  Finance is it's own art form and a foreign language that not everyone speaks.  Same as science.  We need both here.  I've seen it over and over again in my other investments.  THTX is failing us in this regard.  

 

 

 




<< Previous
Bullboard Posts
Next >>